et al
International Research Center, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio, 1815; Bloco A, 1o SS, São Paulo, SP 01327-001, Brazil EMS Pharmaceutical provided the study drugs
to investigate the use of hydroxychloroquine (HCQ) and chloroquine (CQ) with or without a macrolide in
Observational Study of Hydroxychloroquine in Covid-19 Among 1376 patients with Covid-19 admitted to a New York City hospital, 59% were treated with
S
Early during the SARS-CoV-2 pandemic, based on in vitro antiviral activity of both chloroquine and hydroxychloroquine (HCQ) against SARS-CoV
Conversely in large retrospective studies, hydroxychloroquine plus azithromycin treatment was associated with (1) a shorter duration of viral shedding and a decreased risk of transfer to ICU or mortality in ambulatory patients 11 and (2) a decreased mortality in hospitalized patients
Due to the availability and proven clinical record of hydroxychloroquine (HCQ) and chloroquine (CQ) in various human diseases, there have been enormous efforts in repurposing these two drugs as therapeutics for COVID-19
Hydroxychloroquine has been widely promoted as a potential therapy for COVID-19 due to its anti-inflammatory effects and in vitro studies suggesting antiviral activity
The first study claiming HCQ is effective against COVID was criticized by science fraud expert A study of nearly 1,400 patients with moderate to severe COVID-19 disease at a single New York hospital found that patients who received the drug fared no better than patients who did not receive the drug
Our study included a large number of patients across multiple geographic regions and provides the most robust real
Doctors have used hydroxychloroquine for decades to treat Hydroxychloroquine (HCQ) sulfate, a derivative of CQ, there is a lack of studies on the impact of HCQ on the morphology and pH values of endosomes/lysosomes
While slow and arduous, the graduated progression of a candidate therapy from in vitro effect, to animal models, to progressively larger clinical trials is critical to avoid the misguided prioritization of agents with few prospects for success but with risks of diverting scarce resources and exposing patients to potential harm
1 In this trial, p